A de-risked, first-in-class therapeutic to meet the need for a new generation of safe, effective, and non-addictive pain treatment. This agent is a repurposed FDA-approved drug for the treatment of chronic pain, with a lead indication in Fibromyalgia. Its  novel mechanism of action (MoA) is supported by robust preclinical data and a meta-analysis of over 12,000 patients from prior clinical trials demonstrating a statistically significant analgesic effect.